Cellular cofactors of lentiviral integrase: from target validation to drug discovery

Oliver Taltynov1, Belete A Desimmie, Jonas Demeulemeester

  • 1The Laboratory for Molecular Virology and Gene Therapy, KU Leuven, Leuven, Flanders, Belgium.

Insights

Identifying cellular cofactors essential for lentivirus replication, like lens epithelium-derived growth factor (LEDGF/p75) and transportin-SR2 (TRN-SR2), offers new antiviral targets. Inhibiting protein interactions, such as LEDGF/p75 with integrase (IN), is a promising HIV treatment strategy.

Area of Science:

  • Virology
  • Molecular Biology
  • Drug Discovery

Background:

  • Lentiviruses rely on host cell proteins (cofactors) for their life cycle.
  • Host-viral protein interactions during early infection are key antiviral targets.
  • HIV-1 integrase (IN) mediates viral DNA integration and nuclear import.

Purpose of the Study:

  • To explore cellular cofactors as novel antiviral targets.
  • To validate methods for identifying and validating new cofactors.
  • To highlight advancements in small-molecule inhibitors targeting HIV-1 IN.

Main Methods:

  • Focus on lens epithelium-derived growth factor (LEDGF/p75) and transportin-SR2 (TRN-SR2) as model cofactors.
  • Review strategies for cofactor identification and validation.
  • Discuss the development of small-molecule inhibitors (LEDGINs).

Main Results:

  • LEDGF/p75 is a well-characterized cofactor of HIV-1 IN.
  • TRN-SR2 is implicated in HIV-1 nuclear import.
  • Small molecules blocking LEDGF/p75-IN interaction are in development for HIV treatment.

Conclusions:

  • Targeting cofactor-IN interactions presents a viable strategy for antiviral drug development.
  • LEDGINs show promise as therapeutic agents against HIV infection.
  • Further research into novel cofactors can yield new targets for combating lentiviral infections.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...